

revvity

J.P. Morgan Healthcare Conference

January 13, 2025



Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to the Company's customers and end-markets, plans concerning business development opportunities, and acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that the Company's assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in the Company's most recent quarterly report on Form 10-Q and in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also includes non-GAAP financial measures. Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The amounts and timing of such events and items could be material to the Company's results prepared in accordance with GAAP.

Financial Disclosures

Segment and business unit financial metrics presented and discussed today reflect management's estimates of the Company's new operating and reporting structure that became effective in Fiscal Year 2025 (December 30, 2024), and are subject to change

Estimated future results and historical growth rates presented and discussed today are based on 2024 guidance as provided on November 4, 2024 (2024E) and include:


- Proforma results from recent acquisitions
- Non-COVID financials

Key Definitions:

- LSD = 1-3%
- MSD = 4-6%
- HSD = 7-9%
- LDD = 10-12%
- LRP = Long-range plan

“This is the story you are going to hear...


we’re revolutionizing science and transforming human lives with groundbreaking innovation.”



We reimagined our portfolio by acquiring leading scientific offerings and expertise

Legacy




Today



Revvity at-a-glance

An innovative and differentiated Life Sciences and Diagnostics company

~\$2.8B in revenue (2024E)



*Consumables, services and software



Powered by **11,000+** employees collaborating to pioneer groundbreaking solutions


Uniquely positioned in specialized, high-growth markets, serving a diverse customer base

Life Sciences

Overview

Providing reagents, instruments, software and technology services, enabling pre-clinical R&D discovery and drug development

Segment breakdown (2024E) Revenue




- ~85% Life Sciences Solutions
- ~15% Software

Key customers

- Pharma / Biotech
- Academia / Government

Diagnostics


Providing assays, instruments, software and clinical lab services, enabling precision medicine and specialty diagnostic testing



- ~60% Immuno-diagnostics
- ~40% Reproductive Health

- Public Health Labs
- Reference Labs
- Hospitals / Clinics

Life Sciences at-a-glance



HSD
5-year historical average organic growth

~33%
Adjusted operating margin (2024E)

Market overview

\$30B+
TAM

MSD
5-year market CAGR

- Highly innovative reagents and instrumentation
- Transformed portfolio
- Full solutions to enhance customer productivity
- Pursuing adjacent opportunities for additional growth

Strong competitive positioning in innovative areas of Life Sciences


Key areas of focus



Reagents

Investigating the function of genes, proteins and cells to accelerate research and drive discovery

>75k
Reagents offered



Cell analysis reagents

Gene and cell modulation



Microscopy reagents



Instruments

Leading instrument platforms for specialty pre-clinical research applications

>35k
Installed systems



In-vivo imaging

High-content screening



Automated cell counting



Signals Software

Supporting research informatics and clinical analytics workflows with comprehensive SaaS solutions

1M+
Users



signalsNotebook



signalsClinical




signalsResearch




Technology and licensing

Novel technologies aimed at accelerating innovation

>150
Licensees




Viral vectors



Pin-Point™ base editing

Diagnostics at-a-glance



Market-leading specialty diagnostics portfolio | Complete solutions for screening, early diagnosis, intervention, and informing treatment | Driving innovation and expanding global capabilities

Comprehensive solutions for high-precision clinical testing

Key areas of focus



Autoimmunity and allergy


Wide range of assays and innovative automation platforms for fast and accurate diagnostics



Autoimmune assays




Automated analyzers



Emerging infectious disease

Extensive suite of assays to assess acute and ongoing infections or to follow disease progression



Cell isolation systems



Infectious disease assays



Newborn screening (NBS)

Complete lab solutions from sample to results, ensuring early detection and improved health outcomes



Complete NBS workflow management



NBS analyzers




Clinical laboratories

Global laboratories offer diverse clinical populations to improve diagnostic access and data interpretations



Bridging the gap from discovery to cure


as a key player in high-value areas of the drug development lifecycle



Focusing on specialized areas requiring innovation, not routine offerings, and connecting our unique capabilities to meet customer needs




Uniquely
differentiated
in three ways:



Serving our customers as strategic partners



APPROACH



Strategic partnerships with Pharma / Biotech across our portfolio to **drive additional upside** vs. the underlying market

Providing high-value, non-commoditized offerings



PRODUCTS

Examples of unique products:




Life Sciences



Diagnostics

Novel Antibodies and Specialty Reagents



TotalSeq™

Leading reagents portfolio of solutions for precise and reliable results

Research Platform



revvity
signals

Comprehensive and scalable suite of data management and workflow solutions for scientists

Automated Newborn Screening Workflow



Eonis Q System

Unmatched breadth and depth of reproductive health offerings

Automated Indirect Immunofluorescence Testing



UNIQO 160




Autoimmune Testing Menu

Broad menu of autoimmune tests supported by differentiated automation solutions

Products that empower customers to drive scientific insights and advance innovative solutions

Driving faster growth and greater profitability...



Reaffirming our LRP financial targets: **6-8% organic growth in normal market environment (+MSD)**

...Supported by the implementation of our transformed operating model

The Revvity Business Model




Accountability

Articulating consistent operating philosophies to bridge strategy and execution



Agility

Propelling internal innovation and technological advancements to meet customer needs



Digitalization

Building dynamic enterprise architecture to drive valuable insights and enable execution




Talent

Establishing a strong foundational culture to support and develop our talent


Driving innovation, customer satisfaction and strong financial performance

Strong and differentiated financial outlook

Long-term outlook



Financial considerations for 2025



Bringing it all together

A Category of One



An innovative **Life Sciences** and **Diagnostics** company with a unique portfolio and leading positions in high-growth end-markets



Well-positioned with high recurring revenue along with compelling growth opportunities and resilient returns



A **strategic partner** to customers bridging the gap from pre-clinical to clinical stages



A company with a **transformed** portfolio that is **execution** focused



A **differentiated financial profile** with attractive margin expansion potential and **meaningful** capital deployment opportunities

Expanding the
boundaries of human
potential through science

